Lafutidine

Drug Profile

Lafutidine

Alternative Names: FRG 8813; loctidine; Protecadin; Stogar

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Fujirebio
  • Developer Boryung Pharmaceutical; Taiho Pharmaceutical
  • Class Acetamides; Antiulcers; Cytoprotectives; Gastric antisecretories; Piperidines; Pyridines; Small molecules
  • Mechanism of Action Histamine H2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gastric ulcer; Gastritis; Peptic ulcer; Reflux oesophagitis
  • Discontinued Inflammatory bowel diseases

Most Recent Events

  • 30 Nov 2015 Boryung completes phase I clinical trials for Peptic ulcer in South Korea (PO) (NCT02581696)
  • 01 Oct 2015 Phase-I clinical trials in Peptic ulcer in South Korea (PO) (NCT02581696)
  • 01 Nov 2011 Phase-III clinical trials in Reflux oesophagitis in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top